All In Biotech

Drug Trial Radar · NCT05291676

Systems Investigation of Vaccine Responses in Aging and Frailty

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Nov 6, 2023

Primary completion

May 2029

Study completion May 2029

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Mar 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will compare the immune response signatures (including immunologic, transcriptomic and metabolomic) of the two influenza vaccines approved for use in adults age 65 and over (Fluad and Fluzone High-Dose).

Conditions

  • Influenza

Interventions

  • FluzoneBiological

    Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer

  • FluadBiological

    Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in production of IL-6 in monocytes to assess innate immune inflammatory responseTime frame: Baseline and at Day 2, 7, and 28 post-vaccine

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yale School of Medicine

    New Haven, Connecticut · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.